American Shared Hospital Services (NYSE American: AMS), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, announced today that it will release its first quarter 2026 financial results before the market opens on May 14, 2026. The Company will host a conference call at 12:00 PM ET on the same day to discuss the results.
The conference call is a key opportunity for investors and analysts to gain insights into the Company's performance during the first quarter. American Shared Hospital Services operates through equipment leasing and direct patient care services, and its results are closely watched as indicators of trends in cancer treatment technology adoption. The call will be led by Ray Stachowiak, Executive Chairman, who will provide an overview of the financial highlights and operational achievements.
To participate in the call, domestic callers can dial 1-844-413-3972 and international callers can dial 1-412-317-5776 at least ten minutes prior to the start. A simultaneous webcast will be accessible through the Company's website at www.ashs.com or directly via this link. For those unable to attend live, a replay will be available from May 14 through May 21, 2026, by dialing 1-855-669-9658 or 1-412-317-0088 with access code 6753554. The replay will also be archived on the Company's website.
American Shared Hospital Services provides turnkey solutions to cancer treatment centers, health systems, and cancer networks across North and South America. The Company partners with healthcare providers to develop and expand cancer service lines, offering integrated care in community settings. Revenue from these partnerships is derived from shared capital investment and profitability based on ownership interests.
The announcement of the earnings call comes at a time when the Company is focused on expanding its Gamma Knife, proton therapy, and advanced radiation therapy services. These technologies represent significant growth areas in oncology, as they offer non-invasive treatment options with high precision. The financial results will provide clarity on the Company's progress in these segments and its overall financial health.
Investors should note that the press release may contain forward-looking statements regarding the Company's financial condition and future plans. These statements involve risks and uncertainties, including economic conditions, compliance with debt covenants, variability of quarterly results, changes in CMS reimbursement rates, and the timing and financing of expansion projects. For a detailed discussion of these risks, refer to the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025.
